title: Preference for CD4-guided versus continuous HARRT in Thailand.
abstract: Nineteen patients who completed a 27-month CD4-guided structured treatment interruption (STI) trial that showed similar efficacy in STI and continuous arms were asked to choose CD4-guided versus continuous HAART after the study ended. Six chose STI and 13 chose continuous HAART. Reasons for not choosing STIs were fear of developing HIV-related illnesses (38%), fear of CD4 drop (30.8%), fear of viral load increase (7.7%) and ease (7.7%). Those who preferred CD4-guided HAART had a higher median CD4 count nadir during STI and fewer on-off cycles. This study provides an important insight into the preference of patients towards STI in a resource-limited setting.
authors: The HIV Netherlands Australia Thailand Research Collaboration and The Thai Red Cross AIDS Research Center, Bangkok, Thailand. wadchara.p@hivnat.org
authors: J
authors: J
authors: Ananworanich
authors: W
authors: W
authors: Pumpradit
authors: W
authors: W
authors: Apateerapong
authors: U
authors: U
authors: Siangphoe
authors: S
authors: S
authors: Saenawat
authors: P
authors: P
authors: Phanuphak
authors: B
authors: B
authors: Hirschel
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count / Q000379:methods*; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D013785:Thailand; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents